Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on April 24, 2025
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the …
Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025
GlobeNewswire
·
April 24, 2025
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos’ senior management team will …
Krystal Biotech to Present at Upcoming Scientific Conferences
GlobeNewswire
·
April 24, 2025
PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and …
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
GlobeNewswire
·
April 24, 2025
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …
Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting
GlobeNewswire
·
April 24, 2025
CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of …
X4 Pharmaceuticals Announces Reverse Stock Split
GlobeNewswire
·
April 24, 2025
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of directors has determined to effect a one-for-thirty …
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
GlobeNewswire
·
April 24, 2025
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer. The …
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
GlobeNewswire
·
April 24, 2025
April 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada …
Autonomize AI Prior Authorization Copilot: Helping Patients Get Care Faster, Safer, and with Less Stress
GlobeNewswire
·
April 24, 2025
AUSTIN, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomize AI, the leader in healthcare-native AI, today announced a major update to its Prior Authorization Copilot that is delivering rapid, patient-centered improvements across U.S. health plans. The …
ORYZON Raises €30 Million in Capital Increase
GlobeNewswire
·
April 24, 2025
Issued 12,765,958 new shares Priced at €2.35 per share, representing a 15.44% discount on the 5-day VWAP Strong investor demand, with the offering significantly oversubscribed €15 million anchored by a leading US institutional investor Proceeds to fund …
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
GlobeNewswire
·
April 24, 2025
WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who …
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
GlobeNewswire
·
April 24, 2025
TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month …
Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained
GlobeNewswire
·
April 24, 2025
Eagle, Idaho, April 24, 2025 (GLOBE NEWSWIRE) -- There are some occurrences inside the human body that remain a mystery to the medical community. Nerve discomfort is among these mysteries. Knowing that the pain in the fingers, legs, and feet is caused by …
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
GlobeNewswire
·
April 24, 2025
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient Treatment well-tolerated and patient remains on study with stable disease elsewhere Sustained clinical response …
Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
GlobeNewswire
·
April 24, 2025
Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study. Capital raised to date provides strong financial position to prepare the device for regulatory trials and submissions. BOSTON, …
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
GlobeNewswire
·
April 24, 2025
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GLOBE …
Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
GlobeNewswire
·
April 24, 2025
AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potent monotherapy with broad application in oncology Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple …
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
GlobeNewswire
·
April 24, 2025
Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs, will be presented by the lab of Luca Busino, PhD, from the University of Pennsylvania, on April 27th SEED’s first IND candidate …
Mitolyn Reviews 2025: Why This Non-Stimulant Best Weight Loss Supplement Is a Game-Changer for Fat Burn and Metabolism
GlobeNewswire
·
April 24, 2025
Tallmadge, Ohio, April 24, 2025 (GLOBE NEWSWIRE) -- As more health-conscious individuals seek safer, stimulant-free alternatives for weight management in 2025, natural supplements are becoming the gold standard. Crash diets, intense fitness programs, and …
CRB Appoints Ken Olson as Chief Financial Officer
GlobeNewswire
·
April 24, 2025
Kansas City, Missouri, April 24, 2025 (GLOBE NEWSWIRE) -- CRB, a leading global provider of sustainable engineering, architecture, construction and consulting solutions to the life sciences and food and beverage industries, today announced the appointment …